Vasostatin, a fragment of calreticulin, was transfected in the BON cell line to evaluate the feasibility of using it for gene therapy in neuroendocrine tumors. Vasostatin transfected cells were subcutaneously inoculated in nude mice. Burkitt lymphoma cell line, CA46, colorectal adenocarcinoma cell line, SW480, as well as endothelial cells PAE and SVEC4 were used for evaluating the function of vasostatin. The results demonstrated that vasostatin transfer caused enhanced malignant behavior of neuroendocrine tumor cell line, BON. Cell adhesion, spreading and cellular invasion were also enhanced in vasostatin-expressing BON cells. Tumor suppressor genes including p53, nm23, Rb and vinculin were down-regulated. Moreover, cell cycle regulatory protein, p27kip1, and cell differentiation-related protein kinase, PKR, were also significantly down-regulated. Furthermore, expression of NKG2D ligands, MICA and MICB, were down-regulated. Mice implanted with vasostatin-expressing BON cells showed an earlier and faster tumor growth compared to wild type. Anti-proliferative effects of vasostatin could not be proven in other cells except in PAE. These results indicated that vasostatin does probably not have a tumor growth inhibitory effect by itself, but rather modulates processes which are necessary for tumor growth. Therefore, one should be very careful when using vasostatin as an anti-tumoral agent in clinical trials, at least for neuroendocrine tumors.

Keywords:
Calreticulin, Neuroendocrine tumors, Vasostatin, Tumor suppressor gene, Molecular neuroendocrinology
1.
Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O: Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003;47:149–161.
2.
Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353–364.
3.
Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000;407:249–257.
4.
Pike SE, Yao L, Setsuda J, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Atreya CD, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G: Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 1999;94:2461–2468.
5.
Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G: Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998;188:2349–2356.
6.
Xiao F, Wei Y, Yang L, Zhao X, Tian L, Ding Z, Yuan S, Lou Y, Liu F, Wen Y, Li J, Deng H, Kang B, Mao Y, Lei S, He Q, Su J, Lu Y, Niu T, Hou J, Huang MJ: A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther 2002;9:1207–1213.
7.
Evers BM, Ishizuka J, Townsend CM Jr, Thompson JC: The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann NY Acad Sci 1994;733:393–406.
8.
Zhou Y, Wang S, Yue BG, Gobl A, Oberg K: Effects of interferon-α on the expression of p21cip1/waf1 and cell cycle distribution in carcinoid tumors. Cancer Invest 2002;20:348–356.
9.
Coghill ID, Brown S, Cottle DL, McGrath MJ, Robinson PA, Nandurkar HH, Dyson JM, Mitchell CA: FHL3 is an actin-binding protein that regulates α-actinin-mediated actin bundling: FHL3 localizes to actin stress fibers and enhances cell spreading and stress fiber disassembly. J Biol Chem 2003;278:24139–24152.
10.
Radhika V, Onesime D, Ha JH, Dhanasekaran N: Gα13 stimulates cell migration through cortactin-interacting protein Hax-1. J Biol Chem 2004;279:49406–49413.
11.
Oki N, Matsuo H, Nakago S, Murakoshi H, Laoag-Fernandez JB, Maruo T: Effects of 3,5,3′-triiodothyronine on the invasive potential and the expression of integrins and matrix metalloproteinases in cultured early placental extravillous trophoblasts. J Clin Endocrinol Metab 2004;89:5213–5221.
12.
Zhou Y, Gobl A, Wang S, Jacobsen MB, Janson ET, Haines GK 3rd, Radosevich JA, Oberg K: Expression of p68 protein kinase and its prognostic significance during IFN-α therapy in patients with carcinoid tumours. Eur J Cancer 1998;34:2046–2052.
13.
Zhou Y, Wang S, Gobl A, Oberg K: The interferon-α regulation of interferon regulatory factor (IRF)-1 and IRF-2 has therapeutic implications in carcinoid tumors. Ann Oncol 2000;11:707–714.
14.
Hsu LC, Park JM, Zhang K, Luo JL, Maeda S, Kaufman RJ, Eckmann L, Guiney DG, Karin M: The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 2004;428:341–345.
15.
Donze O, Deng J, Curran J, Sladek R, Picard D, Sonenberg N: The protein kinase PKR: a molecular clock that sequentially activates survival and death programs. EMBO J 2004;23:564–571.
16.
Zhou Y, Wang S, Gobl A, Oberg K: Inhibition of CDK2, CDK4 and cyclin E and increased expression of p27Kip1 during treatment with interferon-α in carcinoid tumor cells. J Biol Regul Homeost Agents 1999;13:207–215.
17.
Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003;3:781–790.
18.
Cerwenka A, Lanier LL: NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 2003;61:335–343.
19.
Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727–729.
20.
Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M: RNA interference targeting transforming growth factor-β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 2004;64:7596–7603.
21.
Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH: The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002;17:19–29.
22.
Vetter CS, Lieb W, Brocker EB, Becker JC: Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. Br J Cancer 2004;91:1495–1499.
23.
Li Z, Stafford WF, Bouvier M: The metal ion binding properties of calreticulin modulate its conformational flexibility and thermal stability. Biochemistry 2001;40:11193–11201.
24.
Nakamura K, Zuppini A, Arnaudeau S, Lynch J, Ahsan I, Krause R, Papp S, De Smedt H, Parys JB, Muller-Esterl W, Lew DP, Krause KH, Demaurex N, Opas M, Michalak M: Functional specialization of calreticulin domains. J Cell Biol 2001;154:961–972.
25.
Tutuncu L, Stein P, Ord TS, Jorgez CJ, Williams CJ: Calreticulin on the mouse egg surface mediates transmembrane signaling linked to cell cycle resumption. Dev Biol 2004;270:246–260.
26.
Yao L, Pike SE, Setsuda J, Parekh J, Gupta G, Raffeld M, Jaffe ES, Tosato G: Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 2000;96:1900–1905.
27.
Kageyama S, Isono T, Iwaki H, Wakabayashi Y, Okada Y, Kontani K, Yoshimura K, Terai A, Arai Y, Yoshiki T: Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem 2004;50:857–866.
28.
Usui T, Yamagami S, Yokoo S, Mimura T, Ono K, Amano S: Gene expression profile in corneal neovascularization identified by immunology related macroarray. Mol Vis 2004;10:832–836.
29.
Murphy-Ullrich JE: The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest 2001;107:785–790.
30.
Coppolino MG, Woodside MJ, Demaurex N, Grinstein S, St-Arnaud R, Dedhar S: Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature 1997;386:843–847.
31.
Weis WI: Cell biology: how to build a cell junction. Nature 2004;430:513–515.
32.
Rudiger M: Vinculin and α-catenin: shared and unique functions in adherens junctions. Bioessays 1998;20:733–740.
33.
Subauste MC, Pertz O, Adamson ED, Turner CE, Junger S, Hahn KM: Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility. J Cell Biol 2004;165:371–381.
34.
Propato A, Cutrona G, Francavilla V, Ulivi M, Schiaffella E, Landt O, Dunbar R, Cerundolo V, Ferrarini M, Barnaba V: Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming. Nat Med 2001;7:807–813.
35.
Jockusch BM, Rudiger M: Crosstalk between cell adhesion molecules: vinculin as a paradigm for regulation by conformation. Trends Cell Biol 1996;6:311–315.
36.
Demali KA: Vinculin – a dynamic regulator of cell adhesion. Trends Biochem Sci 2004;29:565–567.
37.
Motomura W, Takahashi N, Nagamine M, Sawamukai M, Tanno S, Kohgo Y, Okumura T: Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int J Cancer 2004;108:41–46.
38.
Blain SW, Scher HI, Cordon-Cardo C, Koff A: p27 as a target for cancer therapeutics. Cancer Cell 2003;3:111–115.
© 2005 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.